<DOC>
	<DOCNO>NCT01609062</DOCNO>
	<brief_summary>The primary objective study evaluate safety 2.0 mg/kg/week 4.0 mg/kg/week BMN 110 patient Morquio A syndrome 196 week . Secondary objective investigate effect two dos exercise capacity 196 week . In addition , pharmacokinetic ( PK ) parameter dose BMN 110 assess .</brief_summary>
	<brief_title>Safety Exercise Study Two Doses BMN 110 Morquio A Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis IV</mesh_term>
	<criteria>Is willing able provide write , sign inform consent ( patient 's legally authorize representative ) nature study explain prior performance research related procedure . Also , patient meet country local age requirement informed consent must willing able provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior performance researchrelated procedure . Has document clinical diagnosis Morquio A Syndrome ( MPS IVA ) base clinical sign symptom MPS IVA document reduce fibroblast leukocyte Nacetylgalactosamine6sulfatase ( GALNS ) enzyme activity genetic test confirm diagnosis MPS IVA . Is least 7 year age Is able walk â‰¥ 200 meter assess 6minute Walk Test ( 6MWT ) If sexually active , willing use acceptable method contraception participate study If female childbearing potential , must negative pregnancy test Screening Visit willing additional pregnancy test study Is willing able perform study procedure , include cardiopulmonary exercise testing ( CPET ) Inability perform exercise test due limited mobility Body weight great 95 kg Screening Severe , untreated sleep apnea measure Screening home sleep test device Patients history , current condition sleep apnea sleep disorder breathe adequate treatment may enrol approve medical monitor . Requirement supplemental oxygen Use ventilator assistance 3 month prior study entry Use positive airway pressure ( continuous positive airway pressure , CPAP , bilevel airway pressure ) treatment sleep apnea sleep disorder breathing allow setting stable least 1 month prior study entry , approve medical monitor . Has concurrent disease condition , include limited , symptomatic cervical spine instability , clinically significant spinal cord compression , severe cardiac disease would interfere study participation , pose safety risk , determine Investigator Has previous hematopoietic stem cell transplant ( HSCT ) Has receive previous treatment BMN 110 Has know hypersensitivity BMN 110 excipients Has major surgery within 3 month prior study entry planning major surgery duration study Use investigational product ( IP ) investigational medical device within 30 day prior begin Screening Period require investigational agent prior completion schedule study assessment Is pregnant breastfeed Screening Period plan become pregnant ( self partner ) time study Has concurrent disease condition may interfere study participation safety , and/or ability perform study procedure determine Investigator Has condition , view Investigator , pose safety risk patient Has condition , view Investigator , place patient high risk poor treatment compliance completing study</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Mucopolysaccharidosis IVA Type A</keyword>
	<keyword>MPS IVA Type A</keyword>
	<keyword>Mucopolysaccharidosis IVA</keyword>
	<keyword>MPS IVA</keyword>
	<keyword>Morquio A Syndrome</keyword>
	<keyword>Lysosomal Storage Disorder</keyword>
	<keyword>LSD</keyword>
	<keyword>N-acetylgalactosamine-6-sulfatase</keyword>
	<keyword>N-acetylgalactosamine-6-sulfate</keyword>
	<keyword>sulfatase</keyword>
	<keyword>galactose-6-sulfatase</keyword>
	<keyword>GALNS</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>ERT</keyword>
	<keyword>MOR-008</keyword>
	<keyword>CPET</keyword>
	<keyword>MST</keyword>
	<keyword>muscle strength test</keyword>
	<keyword>physiological effect</keyword>
</DOC>